Novo Nordisk (NVO): Momentum Continues While Valuation Remains ‘Not Too’ Expensive
[ad_1] puhimec Pharmaceutical stocks have been a nascent space of safety and growth in a volatile market over the last year plus. The group rallied hard on a relative basis…
China’s fourth-quarter and full-year GDP: five things to watch
[ad_1] China’s National Bureau of Statistics will on Tuesday release what is likely to be its third consecutive disappointing estimate for quarterly expansion, as the world’s second-largest economy falls well…
USO: Oil Outlook Turns Bullish (NYSEARCA:USO)
[ad_1] Torsten Asmus I last wrote about the United States Oil ETF, LP (NYSEARCA:USO) in April 2022, when I argued that after a 350% rally since the crisis that gripped…
UK to tighten anti-protest measures, despite criticism from rights groups
[ad_1] Rishi Sunak will on Monday propose new measures to help the police stop disruptive public protest in Britain, heading further down a route that has drawn heavy criticism from…
Amicus: While Pompe Faces Delay, Troubles Slowly Raise Their Heads (NASDAQ:FOLD)
[ad_1] Pgiam/iStock via Getty Images There is no further clarity on the delay of the NDA from Amicus Therapeutics (NASDAQ:FOLD) for AT-GAA (ATB200) in Pompe disease. China is facing a…